Liver Cancer Market, [By Cancer Type (Primary Liver Cancer, Secondary Liver Cancer, Benign Tumor); By Therapeutics (Targeted Therapy, Hepatoblastoma, Hepatocellular Carcinoma, Cholangio Carcinoma, Chemotherapy); By End Use (Paediatrics, Adults)]; and Geography - Trend, Analysis and Forecast till 2025

Report Summary

The Global Liver Cancer Market Size is supposed to gain traction owing to the factors such as increasing number of drug approvals, and rising number ongoing clinical trials for the developing effective and cost efficient therapies to treat liver cancer.

Liver cancer is a condition that is found in the liver when normal cells become abnormal in terms of functionality and appearance. The liver is situated at the upper rite of the abdomen, below the diaphragm which is above the stomach. There are several types of liver cancer namely; ‘Hepatocellular carcinoma’, ‘Cholangiocarcinoma’, ‘Liver Angiosarcoma’, and ‘Hepatoblastoma’. Hepatocellular carcinoma is the most common type of liver cancer which contributes about 75% of total number of patients suffering from liver cancer globally. While Cholangiocarcinoma is the second most common type of liver cancer, contributing approximately 15-20% of the total liver cancer cases worldwide.

In some cases, the cancer begins in some other body parts such as colon, lung or breast and then spreads to the liver this is known as metastatic cancer rather than liver cancer. The liver is the largest organ inside the body and performs various functions making it an important part of human body. However, liver cancer does not show any specific set of symptoms. But when the growth of the cancer is noted it causes pain in right side of the stomach. Also the symptoms like weight loss, nauseas, vomiting, fatigue, loss of appetite, and abdominal swelling. These symptoms are non-specific that can occur in any type of cancer. Liver cancers other symptoms include yellowish decolouration of the skin, tender and enlarged liver, and white-coloured stools.

Liver cancer can be diagnosed with the help of ultrasound surveillance, blood test, imaging studies, and liver biopsy. In blood test, the level of alpha-fetoprotein (AFP), which is elevated by 70% in the person suffering from liver cancer. With several ways of diagnosis of liver cancer, it cannot be cured. Mostly, liver cancer is diagnosed at an early stage and can be treated with the help of chemotherapy, targeted therapy, and radiation therapy.

Rising investments for research and developments by the manufacturers, increasing demand for targeted therapies like CAR-T treatments for liver cancer, and early diagnosis of liver cancer to support the growth of global liver cancer market.

The global market is primarily driven by the factors such as growing number of patients suffering liver cancer due to excessive intake of alcohol globally. Moreover, the surge in the incidence of Hepatocellular carcinoma, and increasing awareness about the diagnosis of liver cancer at the early stage is expected to propel growth in this market. Additionally, the ongoing clinical trials, for understanding the effectiveness of various new treatments for liver cancer, and increased government funding for the improvement of healthcare infrastructure in the developing countries are factors assisting growth of this market.

While, increasing number of drug approvals along with the strong presence of key players in North America is expected to have a positive impact of this market in the near future. Also, growing R&D funding and investments by the governments of developing economies, and increased demand for cost-effective and non-invasive diagnostic techniques further enhances the market potential.

However, high cost of targeted therapy as an effective treatment option, and relatively low awareness for targeted treatments in the developing countries can hinder the growth of this market in the near future.

Global Liver Cancer Market Taxonomy

The global market is segmented on the basis of cancer type, therapeutics, end users, and geography.

On the basis of cancer type, market is segmented into:

• Primary Liver Cancer
• Secondary Liver Cancer
• Benign Tumor

On the basis of therapeutics, market is segmented into:

• Targeted Therapy
• Hepatoblastoma
• Hepatocelluar Carcinoma
• Cholangio Carcinoma
• Chemotherapy

On the basis of end use type, market is segmented into:

• 成年人
• Paediatrics
• Others

Geographically, the market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Increased expenditure on R&D for developing new and effective treatments to lead the liver cancer market share in North America region.

North America is expected to dominate the liver cancer market size among the regions during the forecast period. North America holds major share owning to the continuous technological developments by the increasing R&D investments by the major players and government. While, increasing awareness for the use of targeted therapies would also spur the market in North America.

However, the market in Asia Pacific region is estimated to grow rapidly due to the factors such as increasing awareness for the various effective treatment.

Key players in the global liver cancer market are:

• AbbVie, Inc.
• Pfizer, Inc.
• Onyx Pharmaceutical Inc.
• Hoffmann-La Roche Ltd.
• Alnylam Pharmaceuticals Inc.
• Bristol-Myers Squibb
• Celsion Corp.
• 拜耳Healthcare AG.
• ArQule Inc.
• Jennerex Biopharmaceutics Inc.
• Johnson & Johnson Inc.
• Eli-Lily and Company